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Abstract 1 
Background: Insulin-like growth factor-1 (IGF-I) is important in normal brain 2 
development, but in the adult brain IGF-I overexpression is a signal for neoplastic 3 
processes.  4 
Methods: We examined the association between circulating concentrations of IGF-I 5 
and IGFBP3 in relation to risk of gliomas (74 low-grade, 206 high-grade gliomas), 6 
meningiomas (n=174) and acoustic neuromas (n=49) using a case-control design 7 
nested in the European Prospective Investigation into Cancer and Nutrition. IGF-I 8 
and IGFBP3 were measured by enzyme-linked immunosorbent assays.Conditional 9 
logistic regression was used to compute odds ratios (OR) and corresponding 95% 10 
confidence intervals (CI). 11 
Results: The risk of low-grade gliomas was elevated with increased IGF-I (OR=3.60, 12 
95% CI 1.11-11.7; top vs. bottom quartile) and decreased with elevated IGFBP-3 13 
concentrations (OR=0.28, 95% CI 0.09-0.84) after mutual adjustment of these two 14 
factors; these results became non-significant after exclusion of the first year of follow-15 
up. No association was observed for high-grade gliomas or meningiomas. Both high 16 
IGF-I and IGFBP-3 concentrations were associated with risk of acoustic neuromas 17 
(IGF-I: OR=6.63, 95% CI 2.27-19.4, top vs. bottom tertile; IGFBP-3: OR=7.07, 95% 18 
CI 2.32-21.6), even after excluding the first year of follow-up.  19 
Conclusion: High concentrations of IGF-I might be positively associated with risk of 20 
low-grade gliomas and acoustic neuromas, although we cannot exclude reverse 21 
causation for low-grade gliomas.  22 
Impact: Factors of the IGF axis might be involved in the etiology of some types of 23 
brain tumors.24 
 5 
Introduction 1 
Tumors of the brain vary widely by degree of malignancy; high-grade gliomas 2 
tend to produce more severe and rapidly progressive symptoms whereas low-grade 3 
gliomas, meningiomas and acoustic neuromas typically produce less severe, 4 
intermittent or slowly progressive symptoms. Besides increasing age, high-dose 5 
radiation, and some hereditary syndromes, no risk factors for brain tumors have been 6 
established and the etiology of brain tumors remains largely unknown (1).  7 
Insulin-like growth factors (IGFs) are multifunctional peptides that regulate cell 8 
proliferation, differentiation, and apoptosis (2). IGF-I is important in normal brain 9 
development to promote the growth process, and deletion of the IGF-I gene is 10 
associated with reduced brain growth and mental retardation (3). In the adult brain, 11 
by contrast, IGF-I over-expression is a signal for neoplastic processes (4), and IGF-I 12 
and -II genes are regularly found to be over-expressed in gliomas and meningiomas 13 
(5). In vitro, IGF-I receptor and IGF binding proteins promote mitogenesis and 14 
differentiation in glial cells, oligodendrocytes, and neural cells (5). While most of IGF-I 15 
and its binding proteins in the circulation is produced by the liver (6), these peptides 16 
are also synthesized locally in most other organs, including the brain and other 17 
neural tissues (7). The actions of IGF-I on neural tissues are influenced by the 18 
endocrine effects of circulating IGF-I, which can enter the central nervous system 19 
(CNS) (5), and paracrine or autocrine effects of IGF-I produced within the tissue 20 
itself.  21 
The hepatic production of IGF-I and of its major plasmatic binding protein 22 
IGFBP-3 is stimulated by growth hormone (GH) (8). Adult height relates to 23 
longitudinal growth rates during childhood and adolescence, which are strongly 24 
influenced by levels of IGF-I, although the association of final body stature with 25 
 6 
circulating IGF-I levels during adulthood is less strong (10). Recently, body height 1 
was found to be positively associated with glioma risk in a US cohort study (9). In 2 
EPIC, body height was associated with IGF-I levels in men, but not in women (11). 3 
Acromegaly, a condition resulting from excessive growth hormone secretion, has 4 
also been found to be associated with an increased risk of CNS tumors (12), 5 
although this may partly be due to pituitary irradiation for treating the adenomas 6 
responsible for the condition. 7 
To date, only one small nested case-control study with 22 glioma cases and 8 
400 controls examined the associations between serum concentrations of IGF-I and 9 
IGF binding protein (BP)-3, the most important binding protein of circulating IGF-I (8), 10 
and glioma risk (13). The authors reported inverse associations of gliomas with both 11 
IGF-I and IGFBP-3 concentrations, although only the association between circulating 12 
IGF-I and gliomas was statistically significant. This observation is not consistent with 13 
findings from many studies that observed direct associations between circulating 14 
IGF-I and the risks of several other types of cancer (14), and contrasts with 15 
observations from experimental and histo-pathological studies indicating that IGF-I 16 
may promote tumor development in the central nervous system (4, 15). 17 
 The aim of this study was to examine the association of IGF-I and IGFBP-3 18 
concentrations with the risk of gliomas, meningiomas, and acoustic neuromas in a 19 
case-control study nested within the European Prospective Investigation into Cancer 20 
and Nutrition (EPIC). 21 
 22 
Material and Methods 23 
Study description.  24 
 7 
EPIC is a prospective cohort study designed to examine the association of diet 1 
and lifestyle with the risk of cancer and other chronic diseases. The cohort 2 
comprising a total of more than 500.000 male and female participants was recruited 3 
in 23 centers in 10 European countries. Participants were recruited between 1992 4 
and 2000; most centers recruited subjects from the general population, but in Utrecht 5 
and Florence only women from breast cancer screening programs were recruited. 6 
Additionally, the Spanish and Italian centers include blood donors and the French 7 
cohort consists of members of a health insurance for state school employees. A high 8 
proportion of participants of the Oxford cohort are vegetarians or health-conscious 9 
volunteers. The cohorts of France, Utrecht, Florence, and Norway include women 10 
only. 11 
Information on lifestyle and diet was collected during baseline examination. 12 
Diet was assessed using country-specific validated dietary assessment instruments 13 
(16, 17). Information on lifestyle factors such as smoking, alcohol consumption, or 14 
physical activity, but also on education, occupation, or medical and reproductive 15 
history has been collected using questionnaires and personal interviews. 16 
Anthropometric measurements have been conducted during baseline examination 17 
(18).  18 
Following a standardized protocol, a blood sample of 30 mL was collected in 19 
all participating EPIC countries. In most centers, except Oxford, blood samples were 20 
stored protected from light at 5-10°C until further processing and aliquoting. In the 21 
Oxford center, blood samples were collected throughout the United Kingdom and 22 
transported to the laboratory in Norfolk by mail at ambient temperature. In all centers 23 
except Denmark and Sweden, 0.5 ml aliquots of serum, plasma, red blood cells, and 24 
buffy coat were filled into plastic straws and stored in liquid nitrogen at -196°C. In the 25 
 8 
Danish centers, 1 ml aliquots were filled into tubes and stored in the vapor phase of 1 
liquid nitrogen containers (-150°C). In Sweden, the samples were stored at -80°C. 2 
Case assessment and matching.  3 
The follow-up in EPIC is based on population cancer registries in Denmark, 4 
Italy, Netherlands, Spain, Sweden, United Kingdom and Norway. In Germany and 5 
Greece a combination of methods including health insurance records, cancer and 6 
pathology registries, and active follow-up through study subjects and their next-of-kin 7 
was used. Mortality data are also collected from either the cancer registry or mortality 8 
registries at the regional or national level. For each EPIC center, closure dates of the 9 
study period were defined as the latest dates of complete follow-up for both cancer 10 
incidence and vital status (dates varied between centers, from December 2002 to 11 
December 2006). 12 
By December 2006, 799 histologically confirmed primary brain tumor cases 13 
have been recorded in the EPIC database. Of these, we excluded 102 cases 14 
because they did not provide a blood sample at recruitment and a further 103 cases 15 
because the diagnosis was unspecified beyond that of primary brain tumor (ICD-O 16 
M8000). Cases from the center from Malmö were not available for our analyses 17 
(n=68); France was excluded from the analysis as self-reported brain tumors had not 18 
been histologically confirmed when the study was initiated. Nineteen cases were 19 
excluded because of technical problems or insufficient serum volume. The final 20 
analytical sample included 505 primary brain tumors, namely 282 gliomas 21 
[International classification of diseases for oncology (ICD-O) codes M9380 – M9473], 22 
176 meningiomas (ICD-O M9530-M9539), and 49 acoustic neuromas (ICD-O 23 
M9540). In addition, glioma cases were divided into high grade-glioma (ICD-O codes: 24 
M9440/3, M9441/3, M9442/3, M9401/3, M9380/3, M9451/3) and low grade-glioma 25 
 9 
(ICD-O codes: M9382/3, M9383/1, M9384/1, M9390/0, M9394/1, M9400/3, M9411/3, 1 
M9420/3, M9421/3, M9450/3, M9505/1, M9391/3).  2 
Two controls per case were selected, matched for gender, study (recruitment) 3 
centre, age at recruitment, date at blood donation, and fasting status at blood 4 
donation (time since last consumption of foods or drinks; last meal < 6, 3-6, or <3 5 
hours before blood draw). 6 
Hormone assays.  7 
Serum IGF-I and IGFBP-3 concentrations were measured in the Immunoassay 8 
Laboratory at the German Cancer Research Center, Heidelberg, Germany. Both 9 
peptides were analyzed by enzyme-linked immunosorbent assays (ELISAs) 10 
purchased from Beckman Coulter. Prior to total IGF-I analysis, IGF-I was separated 11 
from IGF-I binding proteins by an acid-ethanol extraction step. Cases and matched 12 
controls were measured in singleton within the same batch. Each analytical batch 13 
further included three different serum quality control samples. Laboratory staff was 14 
blinded to the case/control status of the study samples. Mean intra- and inter-batch 15 
coefficients of variation were 2.9% and 14.4% respectively for IGF-I and 1.7% and 16 
15.5% respectively for IGFBP-3. 17 
Statistical analysis. 18 
To examine the association of IGF-I, IGFBP-3, and molar IGF-I/IGFBP-3 ratio 19 
with BMI, Spearman's partial coefficients of correlation adjusted for age, sex and 20 
EPIC recruitment center were computed. 21 
Conditional logistic regression was used to examine the association of IGF-I 22 
and IGFBP-3 concentrations with brain tumor risk. We also computed the molar ratio 23 
of IGF-I to IGFBP-3 (IGF-I/IGFBP-3 ratio) as a marker of the estimated IGF-I level 24 
 10
biologically available to bind to its receptor. Concentrations of IGF-I and IGFBP-3 as 1 
well as IGF-I/IGFBP-3 ratio were categorized into quartiles based on the distribution 2 
among all controls. Due to the small number of acoustic neuromas, we used tertiles 3 
instead of quartiles to examine the respective associations. 4 
Crude models took into account matching criteria; multivariate models 5 
additionally adjusted for body mass index (BMI) (in sex-specific quartiles) or waist-hip 6 
ratio (WHR) (alternatively; in sex-specific quartiles), education (primary school or 7 
less; secondary school; vocational training; university; missing), smoking history 8 
(never, former, current, missing), and physical activity (active, moderately active, 9 
moderately inactive, inactive). Adjustments for these factors did not appreciably 10 
change any of the results and therefore were excluded from the final models. Thus, 11 
only the matching criteria (age, gender, center, follow-up time, time of the day of 12 
blood draw, and fasting status) remained as implicit adjustments controlled for 13 
through the conditional regression models. Further analyses were conducted with 14 
mutual adjustments between IGF-I and IGFBP-3 concentrations. 15 
In sub-analyses, in which we stratified by sex, age at diagnosis (</≥ 60 years 16 
at diagnosis), BMI (</≥ median BMI), and length of follow-up (</≥ median follow-up 17 
time in cases = 4.4yrs), odds ratios (OR) were estimated for continuous 18 
measurements IGF-1, IGFBP-3, and IGF-I/IGFBP-3 ratio transformed on the log2 19 
scale. In this scale, a unit increase corresponds to a doubling of concentration. 20 
Statistical tests for heterogeneity by sex, age at diagnosis, BMI, and length of follow-21 
up were based on chi-square statistics, calculated as the deviations of logistic beta-22 
coefficients observed in each of the subgroups, relative to the overall beta-coefficient. 23 
Finally, we performed sub-analyses excluding cases diagnosed within the first year of 24 
 11
follow-up to examine potential ‘reverse causation’ bias. All analyses were conducted 1 
with SAS version 9.1. 2 
 3 
Results 4 
The median time between date of study recruitment and diagnosis of tumor 5 
among cases was 4.4 years (glioma 4.5, meningioma 4.2, acoustic neuromas 4.1). 6 
Baseline characteristics of cases and controls are shown in Table 1. Cases and 7 
controls did not differ by selected baseline characteristics except that meningioma 8 
cases had a slightly higher BMI than controls. In controls, circulating levels of IGF-I 9 
were not statistically significantly correlated with BMI (Spearman r = 0.01; p-value 10 
0.77), but there were significant correlations of IGFBP-3 (Spearman r = 0.15; p-value 11 
<0.01) and molar IGF-I/IGFBP-3 ratio (Spearman r = -0.09; p-value <0.01) with BMI.  12 
Gliomas. High IGF-I or high IGFBP-3 concentrations were not statistically 13 
significantly associated with glioma risk (Table 2). The strength of the relationship of 14 
IGF-I and IGFBP-3 with gliomas was slightly attenuated after mutually adjusting for 15 
the two factors. Likewise, there was no significant association between molar IGF-16 
I/IGFBP3 ratio and glioma risk. Excluding the first year of follow-up to examine a 17 
potential reverse causation bias did not change the associations between the 18 
measured biomarkers and glioma risk (IGF-I: 1.11, 95% CI 0.68-1.81, top vs. bottom 19 
quartile; IGFBP-3: 0.92, 0.58, 1.46; IGF-I/IGFBP-3: 1.13, 0.67, 1.91). 20 
We conducted sub-group analyses to examine whether the associations between 21 
factors of the IGF-system differed by sex, BMI, age at tumor diagnosis, or length of 22 
follow-up. Besides a statistically significant effect modification of the association 23 
between IGFBP-3 concentration and glioma risk by BMI, we did not observe major 24 
 12
differences between these sub-groups (data not shown). Per doubling in IGFBP-3 1 
concentration, glioma risk decreased by more than 50% (OR=0.48, 95% CI 0.23-2 
0.99) in subjects with normal BMI, but no statistically significant association was seen 3 
in obese subjects (OR=1.26, 95% CI 0.67-2.36; p-heterogeneity=0.048).  4 
High- vs. low-grade gliomas. After stratifying by tumor grade, neither IGF-I nor 5 
IGFBP-3 concentrations were associated with the risk of high-grade gliomas (Table 6 
3). However, although IGF-I and IGFBP-3 were not associated with low-grade 7 
gliomas in the basic model, a high IGF-I concentration was related to an increased 8 
risk of low-grade gliomas after additionally adjusting for IGFBP-3 concentration 9 
(OR=3.60, 95% CI 1.11-11.7; top vs. bottom quartile). In contrast, IGFBP-3 10 
concentration was inversely associated with low-grade gliomas after adjusting for 11 
IGF-I (OR=0.28, 95% CI 0.09-0.84). A high IGF-I/IGFBP-3 ratio was associated with 12 
a non-statistically significant increase in low-grade glioma risk in the categorical 13 
model; a two-fold increase in the ratio yielded an OR=2.80 (95% CI 0.98-7.98). 14 
Excluding the first year of follow-up resulted in an attenuated association of IGF-I 15 
(OR=1.23, 95% CI 0.45-3.36 [2.05, 0.59-7.13 adjusted for IGFBP-3]; top versus 16 
bottom quartile), IGFBP-3 (OR=0.54, 95% CI 0.21-1.38 [0.34, 0.11-1.07 adjusted for 17 
IGF-I]; top versus bottom quartile), and IGF-I/IGFBP-3 (OR=2.01, 95% CI 0.68-5.92; 18 
top versus bottom quartile) with low-grade gliomas. 19 
Meningiomas. As for gliomas, circulating levels of IGF-I and IGFBP-3 as well as the 20 
IGF-I/IGFBP-3 ratio were not associated with meningioma risk (Table 2). Excluding 21 
the first year of follow-up did not materially alter the observed associations for IGF-I 22 
or IGFBP-3, respectively (IGF-1: OR 1.13, 95% CI 0.61, 2.09, top vs. bottom quartile; 23 
IGFBP-3: 1.71, 0.90, 3.27; IGF-I/IGFBP-3: 0.87, 0.47, 1.64). 24 
 13
In subgroup analyses, we observed statistically significant heterogeneity in the 1 
association between IGF-I/IGFBP-3 ratio and meningioma risk by sex and age (data 2 
not shown). The IGF-I/IGFBP-3 ratio was significantly inversely associated with 3 
mengioma risk in men (OR=0.21, 95% CI 0.06-0.75 per doubling in ratio), but not in 4 
women (OR=1.23, 95% CI 0.65-2.33, p-heterogeneity=0.02). Furthermore, the IGF-5 
I/IGFBP-3 ratio was significantly inversely associated with meningioma risk in young 6 
(< 60 years of age at diagnosis; OR=0.43, 95% CI 0.19-0.98 per doubling in ratio), 7 
but not in older cases (OR=1.72, 95% CI 0.74-4.01, p-heterogeneity=0.02). 8 
Acoustic neuromas. We observed positive associations of circulating IGF-1 and 9 
IGFBP-3 concentrations and acoustic neuromas (Table 2). These associations were 10 
attenuated after mutual adjustments between the two peptides, although the ORs in 11 
the highest tertiles remained significantly increased compared with the bottom 12 
tertiles. As expected, the IGF-I/IGFBP-3 ratio showed no association with risk of 13 
acoustic neuroma. The results did not change strongly after we excluded cases that 14 
occurred during the first year of follow-up (IGF-1: OR 6.93, 95% CI 2.24-21.5, top vs. 15 
bottom tertile; IGFBP-3: 6.09, 1.94-19.1; IGF-I/IGFBP-3: 2.66, 0.82-8.67). No 16 
statistically significant heterogeneity by age at diagnosis, length of follow-up, BMI, 17 
and sex were observed (data not shown). 18 
 19 
Discussion 20 
This is the first large nested case-control study to examine the association of 21 
circulating concentrations of IGF-I and its most important binding protein IGFBP-3 22 
with the risk of different types of brain tumor, namely high- and low-grade gliomas, 23 
meningiomas and acoustic neuromas. We did not observe a general association 24 
 14
between IGF-I or IGFBP-3 concentrations or the molar ratio of IGF-I to IGFBP3 with 1 
risk of gliomas and mengiomas. However, subjects with high circulating levels of IGF-2 
I had an increased risk and those with a high level of IGFBP-3 had a decreased risk 3 
of low-grade gliomas after mutual adjustments between IGF-I and IGFBP-3. 4 
Additionally, we observed that both concentrations of IGF-I and IGFBP3 were 5 
positively associated with the risk of acoustic neuromas. 6 
High circulating concentrations of IGF-I and IGF binding proteins have been 7 
found to be associated with increased risks of several types of cancers, including 8 
cancers of the colon (19), prostate (20), or breast cancer (21). There is increasing 9 
evidence that IGFs play an important role in the growth and differentiation of the 10 
central nervous system and specific receptors for IGF-I and IGF-II have been 11 
identified in normal human brain (15). IGF pathways show similar expression and 12 
functional features during central nervous system development and tumorgenesis (8, 13 
22, 23). IGFs have been reported to be over-expressed to varying degrees in central 14 
nervous system tumors, such as glioma (4, 15), and in vitro studies have shown that 15 
IGF-I promotes mitogenesis and differentiation in glial cells (24, 25). IGF binding 16 
proteins prolong the half-life of IGF-I by competing with IGF-I receptor for binding 17 
IGF-I. In addition, IGFBP-3 may have intrinsic growth inhibiting and pro-apoptotic 18 
effects independent of sequestering IGF-I (26, 27), although in some experimental 19 
studies it has also been observed to exert growth-promoting effects (28). IGFBP 20 
expression can increase neoplastic processes, for example in gliomas (29). IGF-I is 21 
produced by the liver, but also in the brain and the spinal cord (22). It has been 22 
shown that circulating IGF-I enters the brain and the spinal cord via a saturable 23 
transport system at the brain-blood barrier (7). The half-life of IGF-I and the rate of 24 
entry of IGF-I into the central nervous system are likely to be related to the 25 
concentration of IGFBPs in the circulation (7). Vice versa, it might be possible that 26 
 15
IGF-I produced by tumor cells in the brain crosses the brain-blood barrier and enters 1 
the circulation. However, the contribution of locally produces IGF-I leaking into 2 
systemic circulation is likely to be small compared with liver production. Based on the 3 
attenuation of the association between IGF-I concentration and risk of gliomas, we 4 
cannot exclude potential reverse causation. 5 
We did not observe strong and consistent associations of circulating levels of 6 
IGF-I, IGFBP-3, or the molar ratio of IGF-I to IGFBP-3 with the risk of gliomas in 7 
general. However, high IGF-I concentrations were positively and high IGFBP-3 8 
concentrations were inversely associated with the risk of low-grade gliomas after 9 
mutual adjustment, whereas no associations were observed for high-grade gliomas. 10 
So far, only one previous epidemiological study examined the association of IGF-I or 11 
IGFBP-3 with gliomas. Lönn et al. observed an inverse association of IGF-I 12 
concentration with glioma risk, but no association with IGFBP-3 concentration in a 13 
case-control study nested within the prospective ATBC trial in Finland (13). 14 
Adjustment for age, BMI, smoking, self-reported history of allergies, education, 15 
intervention group assignment, time period of diagnostic did not change the results. 16 
This study was too small to stratify by glioma grade. In a case-control study, 17 
polymorphisms in IGF-I, IGF-II, IGF-I receptor, IGF-II receptor, and IGFBP-3 genes 18 
were examined in relation to glioma and meningioma risk (28). The majority of SNPs 19 
were not related to glioma risk. Interestingly, however, one SNP in IGF-I and two 20 
SNPs in the IGF-I receptor gene were associated with the risk of low- but not high-21 
grade gliomas. The functionality of these polymorphisms, however, appears to be 22 
unclear and, thus, an interpretation with respect to our results is difficult. However, 23 
one might speculate that there are different genetic pathways that lead to high- and 24 
low-grade glioma. IGF-I receptors are overexpressed in gliomas and meningiomas 25 
and in vitro, IGF-I receptor has been shown to promote mitogenesis and 26 
 16
differentiation in glial cells, oligodendrocytes, and neural cells (5). The associations of 1 
IGF-I and IGFBP-3 concentrations with low-grade gliomas were attenuated and not 2 
statistically significant anymore after excluding the first year of follow-up. This might 3 
be due to the even lower number of cases and, thus, more imprecision, but we also 4 
cannot exclude a certain extend of reverse causation such that the association is 5 
caused by cases diagnosed in the first year of follow-up. However, the number of 6 
cases with low-grade glioma diagnosed in the first or even the first two years is too 7 
small for a meaningful statistical analysis. 8 
Circulating concentrations of IGF-I or IGFBP-3 were generally not associated 9 
with the risk of meningiomas. The only associations observed in our study were a 10 
decreasing meningioma risk with increasing IGF-I/IGFBP-3 ratio in males and in 11 
cases that were diagnosed at an earlier age. However, the implications are unclear, 12 
especially because the number of meningioma cases among men is small (n=45) 13 
and chance might be the reason for this statistically significant finding. This is the first 14 
study to examine this association. Previously, Lönn et al. (28) also did not report any 15 
association of polymorphisms in IGF-I, IGF-II, IGF-I receptor, IGF-II receptor, and 16 
IGFBP-3 genes with meningioma risk.  17 
Acoustic neuromas (vestibular schwannoma) are benign and slowly growing 18 
nerve sheath tumors of the vestibulocochlear nerve. The incidence of this tumor is 19 
growing in recent years although this increase could simply be due to improved 20 
diagnostic technologies (30). The etiology of this tumor is largely unknown besides 21 
an association with moderate to high doses of ionizing radiation, which is a risk factor 22 
for all brain tumors. However, ionizing radiation can explain only a small fraction of 23 
the tumors. To the best of our knowledge, our finding of a direct association of 24 
 17
circulating IGF-I and IGFBP-3 concentrations with acoustic neuromas has not 1 
previously been reported.  2 
The reason for an inverse association of IGFBP-3 with low-grade gliomas after 3 
adjusting for circulating IGF-I and a direct association of IGFBP-3 with acoustic 4 
neuromas is unclear. A positive association of IGF-I with acoustic neuromas is 5 
consistent with IGF-I’s mitogenic effects. The association of IGFBP-3 concentration 6 
with cancer risk has first been thought to be inverse as IGFBP-3 is thought to 7 
determine the concentration of free, i.e., biologically active, IGF-I in the circulation. 8 
However, the results of previous studies on different types of cancer have been 9 
inconsistent with some studies indeed showing inverse associations, but some also 10 
showing no or even a positive association (14). It has been discussed that different 11 
assays measuring concentrations of total or intact IGFBP-3 could cause differences 12 
between studies (14), but this does not explain differences in our study between two 13 
different types of brain tumors, i.e., different effects of IGFBP-3 on low-grade gliomas 14 
and acoustic neuromas. We measured intact IGFBP-3, not total IGFBP-3, which also 15 
includes IGFBP-3 fragments that are less biologically active. 16 
Our study is so far the second study on IGF-I and IGFBP-3 concentration and 17 
risk of brain tumor. Its advantages are its size (505 histologically confirmed primary 18 
brain tumors), the prospective design, and the ability to adjust for a number of 19 
potential confounders. As in most epidemiological studies, we cannot exclude chance 20 
as a possible explanation of our findings, especially as the number of cases in the 21 
groups in which we observed statistically significant associations are small. The 22 
estimates observed in our study may, thus, be an overestimation of the true effect. 23 
Also, the attenuation of the associations observed for low-grade gliomas after 24 
excluding the first year of follow-up supports that our results have to be interpreted 25 
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with care. In addition, we were not able to adjust environmental risk factors such as 1 
ionizing radiation. While there is rationale for an inverse association of IGFBP-3 and 2 
low-grade glioma, the positive association between IGFBP-3 and risk of acoustic 3 
neuromas is difficult to interpret due to the small number of cases. 4 
5 
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